Teva's Reslizumab Faces FDA Questions On Breadth Of Asthma Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Clinical development program's inclusion criteria encompassed moderate-to-severe asthmatics but actually only studied patients with severe disease.